Pulmonology

Systemic sclerosis

Questions discussed in this category

What protective post-op measures do you recommend for a patient with scleroderma and a history of ILD, PH, Raynaud’s and digital ischemia undergoing cardiothoracic surgery?

1 Answer available

How do you approach the management of SSc-ILD in a patient on immune checkpoint therapy?

1 Answer available

How will you use tocilizumab in the treatment algorithm for SSc-ILD, given its recent FDA approval?

1 Answer available

Is there a role for anti-IL6 therapy in SSc-associated ILD?

1 Answer available

What is the role of nintedanib in the treatment of SSc-ILD?

The SENSCIS trial was published in 2019 on efficacy of this agent. However, it's not clear where this should be in the treatment algorithm: Monot...

2 Answers available

Papers discussed in this category

N. Engl. J. Med., 2019 May 20

Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.

The Lancet. Respiratory medicine, 2016-09

Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.

The New England journal of medicine, 2006-06-22

Cyclophosphamide versus placebo in scleroderma lung disease.

Lancet Respir Med, 2020 Aug 28

Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.

Arthritis Rheumatol, 2021 Feb 03

Tocilizumab Prevents Progression of Early Systemic Sclerosis Associated Interstitial Lung Disease.

Related Topics in Pulmonology